BENITEC BIOPHARMA INC (BNTC) Fundamental Analysis & Valuation

NASDAQ:BNTC • US08205P2092

Current stock price

10.27 USD
-0.54 (-5%)
At close:
10.27 USD
0 (0%)
After Hours:

This BNTC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. BNTC Profitability Analysis

1.1 Basic Checks

  • BNTC had negative earnings in the past year.
  • BNTC had a negative operating cash flow in the past year.
  • BNTC had negative earnings in each of the past 5 years.
  • BNTC had a negative operating cash flow in each of the past 5 years.
BNTC Yearly Net Income VS EBIT VS OCF VS FCFBNTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10M -20M -30M -40M

1.2 Ratios

  • BNTC has a Return On Assets (-43.55%) which is comparable to the rest of the industry.
  • BNTC has a Return On Equity of -44.68%. This is in the better half of the industry: BNTC outperforms 67.24% of its industry peers.
Industry RankSector Rank
ROA -43.55%
ROE -44.68%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BNTC Yearly ROA, ROE, ROICBNTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BNTC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BNTC Yearly Profit, Operating, Gross MarginsBNTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5K -10K -15K -20K -25K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. BNTC Health Analysis

2.1 Basic Checks

  • BNTC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BNTC Yearly Shares OutstandingBNTC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
BNTC Yearly Total Debt VS Total AssetsBNTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • An Altman-Z score of 87.63 indicates that BNTC is not in any danger for bankruptcy at the moment.
  • BNTC has a better Altman-Z score (87.63) than 98.27% of its industry peers.
  • BNTC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 87.63
ROIC/WACCN/A
WACCN/A
BNTC Yearly LT Debt VS Equity VS FCFBNTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 46.95 indicates that BNTC has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 46.95, BNTC belongs to the top of the industry, outperforming 99.23% of the companies in the same industry.
  • BNTC has a Quick Ratio of 46.95. This indicates that BNTC is financially healthy and has no problem in meeting its short term obligations.
  • BNTC has a Quick ratio of 46.95. This is amongst the best in the industry. BNTC outperforms 99.23% of its industry peers.
Industry RankSector Rank
Current Ratio 46.95
Quick Ratio 46.95
BNTC Yearly Current Assets VS Current LiabilitesBNTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. BNTC Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 69.76% over the past year.
EPS 1Y (TTM)69.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • BNTC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.21% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y19.37%
EPS Next 2Y12.02%
EPS Next 3Y10.21%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BNTC Yearly Revenue VS EstimatesBNTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2027 2028 10M 20M 30M
BNTC Yearly EPS VS EstimatesBNTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

0

4. BNTC Valuation Analysis

4.1 Price/Earnings Ratio

  • BNTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year BNTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNTC Price Earnings VS Forward Price EarningsBNTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNTC Per share dataBNTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.02%
EPS Next 3Y10.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BNTC Dividend Analysis

5.1 Amount

  • BNTC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BNTC Fundamentals: All Metrics, Ratios and Statistics

BENITEC BIOPHARMA INC

NASDAQ:BNTC (3/27/2026, 8:03:16 PM)

After market: 10.27 0 (0%)

10.27

-0.54 (-5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)05-12
Inst Owners96.26%
Inst Owner Change55.62%
Ins Owners0.53%
Ins Owner Change0%
Market Cap351.75M
Revenue(TTM)N/A
Net Income(TTM)-41.82M
Analysts87.69
Price Target25.7 (150.24%)
Short Float %6.06%
Short Ratio11.99
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.27%
Min EPS beat(2)-41.99%
Max EPS beat(2)41.44%
EPS beat(4)3
Avg EPS beat(4)22.44%
Min EPS beat(4)-41.99%
Max EPS beat(4)57.97%
EPS beat(8)4
Avg EPS beat(8)-91.3%
EPS beat(12)6
Avg EPS beat(12)-100.3%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.3%
EPS NY rev (1m)-13.74%
EPS NY rev (3m)-2.98%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.76
P/tB 3.76
EV/EBITDA N/A
EPS(TTM)-1.14
EYN/A
EPS(NY)-1.1
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.65
OCFYN/A
SpS0
BVpS2.73
TBVpS2.73
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -43.55%
ROE -44.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 46.95
Quick Ratio 46.95
Altman-Z 87.63
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.21%
EPS Next Y19.37%
EPS Next 2Y12.02%
EPS Next 3Y10.21%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-104.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.12%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-20.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.59%
OCF growth 3YN/A
OCF growth 5YN/A

BENITEC BIOPHARMA INC / BNTC Fundamental Analysis FAQ

What is the fundamental rating for BNTC stock?

ChartMill assigns a fundamental rating of 3 / 10 to BNTC.


What is the valuation status of BENITEC BIOPHARMA INC (BNTC) stock?

ChartMill assigns a valuation rating of 0 / 10 to BENITEC BIOPHARMA INC (BNTC). This can be considered as Overvalued.


How profitable is BENITEC BIOPHARMA INC (BNTC) stock?

BENITEC BIOPHARMA INC (BNTC) has a profitability rating of 1 / 10.


What is the earnings growth outlook for BENITEC BIOPHARMA INC?

The Earnings per Share (EPS) of BENITEC BIOPHARMA INC (BNTC) is expected to grow by 19.37% in the next year.